欧盟小组在2026-2027年季节支持新的现代COVID疫苗,比以前的疫苗更有效。 EU panel backs new Moderna COVID vaccine, more effective than prior version, for 2026–2027 season.

欧洲药物管理局的CHMP建议批准Moderna的mNEXSPIKE (mRNA-1283),这是一个新的mRNACOVID-19疫苗,适用于12岁及以上的患者,基于第三期试验显示,它比原始Spikevax有效9. 3%,对65岁及以上的成年人更有好处. The European Medicines Agency's CHMP has recommended approval for Moderna’s mNEXSPIKE (mRNA-1283), a new mRNA COVID-19 vaccine for ages 12 and older, based on a Phase 3 trial showing it was 9.3% more effective than the original Spikevax, with greater benefit in adults 65 and older. 10微克剂量显示出类似的安全性,当地反应较少。 The 10 μg dose showed similar safety, with fewer local reactions. 如果得到欧洲委员会的核准,2026-2027年季节可在欧盟使用。 If approved by the European Commission, it could be available in the EU for the 2026–2027 season. 该疫苗已经在美国和加拿大获得批准,现代公司已经向其他市场提出审查申请。 The vaccine is already approved in the U.S. and Canada, and Moderna has filed for review in other markets.